 Dr. Jeremy Fry
Director of Sales
ProImmune Ltd.
United Kingdom |
Title:
Ankyrons® – Advanced Research Tools for Investigating Emerging Infectious Diseases
Abstract:
The rapid evolution of viral and bacterial pathogens presents significant challenges for research. Ankyrons®, synthetic ankyrin-repeat proteins (~15 kDa), provide a versatile and precise tool for studying viral biology, immune responses, and pathogen interactions. Engineered through in vitro ribosome display from a vast (~10¹²) Teralibrary™, Ankyrons can be rapidly generated without animal immunization, offering a scalable, animal-free solution for research needs.
Ankyrons have demonstrated exceptional specificity in binding and neutralizing SARS-CoV-2 variants, including wild-type, Delta, and Omicron. Their small size allows for enhanced cellular penetration, enabling efficient immunofluorescence, flow cytometry, and immunohistochemistry applications. Additionally, Ankyrons are capable of single-residue discrimination, making them ideal for tracking viral mutations and studying the molecular dynamics of viral evolution.
These capabilities extend beyond human pathogens, with Ankyrons also enabling research on animal diseases, including African swine fever, foot-and-mouth disease, and other significant veterinary pathogens. They are also used to study a broad range of protein targets across bovine, porcine, avian, and mosquito species, supporting a One Health research framework that links human, animal, and environmental health.
For virologists, immunologists, and public health researchers, Ankyrons provide a powerful tool to accelerate pathogen characterization, viral evolution studies, and immune response profiling in a cost-effective and adaptable format.
Biography:
Jeremy Fry is an experienced leader with a background in immunology and gene therapy, bringing more than two decades of expertise in driving scientific innovation and commercial strategy. He earned his DPhil from the University of Oxford, where his research focused on immunological tolerance in transplantation. As Director of Sales at ProImmune, Jeremy leads global business development for cutting-edge immunomonitoring technologies, including MHC multimer reagents and T cell epitope mapping solutions. His work plays a pivotal role in advancing research in infectious diseases, vaccine development, and immune profiling. Passionate about bridging the gap between bench science and real-world applications, Jeremy fosters collaborations that accelerate the progress of immune-based therapeutics.
|
